SAMPLES, WORKING STANDARDS AND IMPURITIES AVAILABLE

ABIRATERONE ACETATE (CAS 154229-19-3) is a steroidal antiandrogen, specifically an androgen synthesis inhibitor, used in combination with prednisone in metastatic castration-resistant prostate cancer (formerly hormone-resistant or hormone-refractory prostate cancer) – i.e., prostate cancer not responding to androgen deprivation or treatment with androgen receptor antagonists.

THERAPEUTIC INDICATION: ONCOLOGY

For the treatment of metastatic castration resistant prostate cancer.

MARKET INFORMATION

Originator: JOHNSON & JOHNSON
Originator product: ZYTIGA^®
Core patent exclusivities : US 04/2015; Europe 09/2022

YOUR ADVANTAGES

Manufactured in China
API validated and commercially available
US FDA-inspected manufacturing plant
Samples, working standards and impurities are available
Active US-DMF and ASMF available

^{This article uses material from Wikipedia, which is released under the Creative Commons Attribution-Share-Alike License 3.0.}